J&J's TMC435 Joins The Pharmasset Club

Pharmasset and J&J's Tibotec unit will initiate a Phase II study evaluating the combination of the investigational nucleotide polymerase inhibitor PSI-7977 and protease inhibitor TMC435.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet